Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial
- PMID: 21836413
- DOI: 10.1097/FTD.0b013e31820beb02
Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial
Abstract
Purpose: To evaluate retinal functional changes by multifocal electroretinography (mfERG) after photodynamic therapy with half-dose verteporfin in patients with acute central serous chorioretinopathy.
Methods: Thirty-four patients with acute central serous chorioretinopathy were randomly assigned to receive photodynamic therapy with half-dose verteporfin (n = 24) or placebo (n = 10). Multifocal electroretinography was performed at baseline and at 12 months, and serial changes in response amplitudes were expressed as amplitude ratios. The mfERG amplitude ratios, best-corrected visual acuity, and optical coherence tomography central foveal thickness were compared between the verteporfin and placebo groups. Correlation analysis between the mfERG response amplitude ratios and the best-corrected visual acuity changes and reduction in optical coherence tomography central foveal thickness were also performed.
Results: At 12 months, the mean visual improvement was 1.8 line and 0.1 line for the verteporfin and placebo groups, respectively (P = 0.003). Eyes in the verteporfin group had significantly lower central foveal thickness (P = 0.028) and higher P1 mfERG response ratios for Rings 1 and 2 at 12 months compared with the eyes in the placebo group (P = 0.030 and P = 0.018, respectively). Significant correlations between mfERG N1 and P1 amplitude ratios at the central rings were observed with both changes in best-corrected visual acuity and reductions in optical coherence tomography central foveal thickness (P < 0.05).
Conclusions: Multifocal electroretinography demonstrated higher retinal function at the central macula objectively in central serous chorioretinopathy patients treated with half-dose verteporfin photodynamic therapy. Changes in best-corrected visual acuity and optical coherence tomography central foveal thickness findings also correlated with mfERG responses of the central macula, confirming the usefulness of mfERG as an objective investigation to evaluate the functional changes in central serous chorioretinopathy.
Similar articles
-
Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.Ophthalmology. 2008 Oct;115(10):1756-65. doi: 10.1016/j.ophtha.2008.04.014. Epub 2008 Jun 5. Ophthalmology. 2008. PMID: 18538401 Clinical Trial.
-
Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.Br J Ophthalmol. 2006 Jul;90(7):869-74. doi: 10.1136/bjo.2006.090282. Epub 2006 Apr 5. Br J Ophthalmol. 2006. PMID: 16597666 Free PMC article.
-
A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.JAMA Ophthalmol. 2015 Mar;133(3):333-40. doi: 10.1001/jamaophthalmol.2014.5312. JAMA Ophthalmol. 2015. PMID: 25555191 Clinical Trial.
-
System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy.Acta Ophthalmol. 2014 Dec;92(8):e594-601. doi: 10.1111/aos.12482. Epub 2014 Jul 13. Acta Ophthalmol. 2014. PMID: 25042260 Review.
-
Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.Eye (Lond). 2019 Jul;33(7):1035-1043. doi: 10.1038/s41433-019-0381-7. Epub 2019 Mar 1. Eye (Lond). 2019. PMID: 30824822 Free PMC article. Review.
Cited by
-
Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes.Eye (Lond). 2013 May;27(5):612-20. doi: 10.1038/eye.2013.24. Epub 2013 Mar 22. Eye (Lond). 2013. PMID: 23519277 Free PMC article.
-
Short Term Presence of Subretinal Fluid in Central Serous Chorioretinopathy Affects Retinal Thickness and Function.J Clin Med. 2020 Oct 26;9(11):3429. doi: 10.3390/jcm9113429. J Clin Med. 2020. PMID: 33114519 Free PMC article.
-
Central serous chorioretinopathy: update on pathophysiology and treatment.Surv Ophthalmol. 2013 Mar-Apr;58(2):103-26. doi: 10.1016/j.survophthal.2012.07.004. Surv Ophthalmol. 2013. PMID: 23410821 Free PMC article. Review.
-
Interventions for central serous chorioretinopathy: a network meta-analysis.Cochrane Database Syst Rev. 2015 Dec 22;(12):CD011841. doi: 10.1002/14651858.CD011841.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2025 Jun 16;6:CD011841. doi: 10.1002/14651858.CD011841.pub3. PMID: 26691378 Free PMC article. Updated.
-
Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis.Eye (Lond). 2016 Jan;30(1):15-22. doi: 10.1038/eye.2015.208. Epub 2015 Oct 30. Eye (Lond). 2016. PMID: 26514243 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources